These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

856 related items for PubMed ID: 32531840

  • 1. 68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A.
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [Abstract] [Full Text] [Related]

  • 2. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

  • 3. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy.
    Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J.
    World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT.
    Theranostics; 2017 Nov; 7(6):1770-1780. PubMed ID: 28529650
    [Abstract] [Full Text] [Related]

  • 11. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C.
    Radiat Oncol; 2018 Mar 02; 13(1):37. PubMed ID: 29499730
    [Abstract] [Full Text] [Related]

  • 12. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
    Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A.
    Mol Imaging Biol; 2020 Jun 02; 22(3):788-796. PubMed ID: 31482413
    [Abstract] [Full Text] [Related]

  • 13. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 02; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Aug 02; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 15. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan 02; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 16. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
    Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.
    Lancet Oncol; 2019 Sep 02; 20(9):1286-1294. PubMed ID: 31375469
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery.
    Nandurkar R, van Leeuwen P, Stricker P, Woo H, Kooner R, Yuen C, O'Neill G, Ende D, Cusick T, Ho B, Hickey A, Emmett L.
    Br J Radiol; 2019 Mar 02; 92(1095):20180667. PubMed ID: 30563350
    [Abstract] [Full Text] [Related]

  • 18. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.
    Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M.
    Eur J Nucl Med Mol Imaging; 2019 Sep 02; 46(10):2169-2177. PubMed ID: 31254037
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.
    Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan 02; 46(1):11-19. PubMed ID: 29905907
    [Abstract] [Full Text] [Related]

  • 20. The diagnostic accuracy of 68 Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis.
    Rajwa P, Heidenreich J, Drzezga A, Schmidt M, Shariat SF, Heidenreich A.
    Prostate; 2024 Jan 02; 84(1):74-78. PubMed ID: 37750292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.